

Vortex Biosciences, Inc. Announces Publication in Clinical & Experimental Metastasis Journal, on the use of the VTX-1 System for CTC isolation from patient derived xenograft models of triple-negative breast cancer

April 25, 2020

Vortex Biosciences, a leading provider of circulating tumor cell (CTC) isolation systems and workflows, announces publication in Clinical & Experimental Metastasis Journal using their VTX-1 System. This study assembles a timeline of PDOX tumor shedding and metastatic tumor progression before and after tumor excision surgery. The data collected through these experiments will guide the further use of PDOX models in studying metastatic TNBC

The publication can be viewed here –

<https://link.springer.com/article/10.1007/s10585-020-10033-3>

About Vortex Biosciences

Vortex Biosciences integrates cancer biology, microfluidic engineering, and informatics to advance cancer research and accelerate the development of innovative diagnostics and therapeutics through tools for isolating intact CTCs. The fully automated Vortex VTX-1 instrument harvests intact circulating tumor cells from whole blood samples for use in downstream research and clinical applications such as patient stratification in clinical trials, monitoring disease progression and drug treatment effectiveness. With a mission to enable noninvasive diagnosis of cancer and real-time monitoring throughout a patient's treatment, Vortex is at the forefront of accelerating cancer research and improving patient outcomes. For more information, visit <http://www.vortexbiosciences.com>.